ALSO NOTED: Thailand may bust cancer patents; Watson scores marketing rights from Depomed;

> Thailand is mulling patent-breaking compulsory licenses for three cancer drugs, including one from Novartis, one from Sanofi-Aventis, and one from Genentech. Report

> Depomed and Watson Pharmaceuticals expanded a marketing agreement to give Watson the right to promote the UTI drug ProQuin in the OB/GYN market. Report

> Cubist Pharmaceuticals got Health Canada's OK to market its Cubicin intravenous antibiotic for skin infections and certain gram-positive infections. Report

> Indian drug maker Cadila Pharmaceutical got the FDA's nod for its rheumatoid arthritis remedy hydroxychloroquine sulfate. Report

> Lupin will invest $10 million in a new steroid-manufacturing facility in Indore, India. Report

And Finally... Space-traveling microbes get better, stronger, faster--just what we need, right? Yes, say researchers who think subjecting germs to extreme conditions may lead to new therapies for cancer and infectious disease. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.